Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy

This publication has 38 references indexed in Scilit:

• Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells
  International Immunology, 2005
• The DR4–DQ8 haplotype and a specific T cell receptor Vβ T cell subset are associated with absence of allergy to Can f 1
  Clinical and Experimental Allergy, 2005
• T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity
  PLoS Medicine, 2005
• The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells
  European Journal of Immunology, 2003
• IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy
  European Journal of Immunology, 2003
• Inhibition of human T‐cell responses by allergen peptides
  Immunology, 2001
• β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial
  The Lancet, 2001
• Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats☆☆☆★★★
  Journal of Allergy and Clinical Immunology, 1998
• Altered Peptide Ligand–Induced Partial T Cell Activation: Molecular Mechanisms and Role in T Cell Biology
  Annual Review of Immunology, 1996
• Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
  Nature, 1996